GlassScriptPhysician profile
Maleka Z Ahmed
NPI 1841286721
$3,134.53
in general payments reported to CMS, 2019-2025
40 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $220 · 2021: $610 · 2022: $724 · 2023: $526 · 2024: $524 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.92 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $393.34 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $356.16 | 2019-2025 | Imbruvica, Darzalex, Erleada |
| Pfizer INC. | $245.87 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $225.36 | 2019-2025 | Keytruda, Welireg |
| Daiichi Sankyo INC. | $164.06 | 2021-2024 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $155.73 | 2021-2025 | Ojjaara |
| Kite Pharma, INC. | $131.58 | 2020-2023 | Yescarta |
| Novartis Pharmaceuticals Corporation | $131.23 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $128.12 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $99.00 | 2024 | |
| Myovant Sciences INC. | $85.56 | 2021-2022 | |
| Genzyme Corporation | $84.05 | 2019-2023 | |
| Eisai INC. | $81.20 | 2019-2024 | |
| Gilead Sciences, INC. | $72.98 | 2019 | |
| Genentech USA, INC. | $65.88 | 2019-2023 | Venclexta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maleka Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.